Home > Dermatology > AAD 2022 > Psoriasis: State of the Art > Long-term psoriasis treatment with bimekizumab results in maintained efficacy

Long-term psoriasis treatment with bimekizumab results in maintained efficacy

Presented By
Prof. Kenneth Gordon, Medical College of Wisconsin, USA
Presented by
Kenneth Gordon
Medical Writer
Kenneth Gordon
Conference
AAD 2022
More than 80% of patients with psoriasis preserved their Psoriasis Area and Severity Index (PASI)100 response over 2 years of treatment with bimekizumab in a pooled analysis of several phase 3 trials. The safety results over 48 weeks were consistent with previous shorter-term results. Dual IL-17A/F inhibition with bimekizumab has demonstrated a meaningful benefit for patients with moderate-to-severe plaque psoriasis in various phase 3 clinical trials [1–3]. Its high efficacy is explained by its mechanisms of action (see Figure) [4]. “What happens long-term becomes the critical question,” stressed Prof. Kenneth Gordon (Medical College of Wisconsin, WI, USA). Therefore, a pooled analysis was performed of 5 phase 3 and 3b trials to assess the long-term efficacy and safety of the drug over 2 years [5]. During the initial phase 3 periods, 62.4% (n=850) of the study population on bimekizumab reached PASI100. The 86.9% of responders with a PASI of at least 90 at ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on